-+ 0.00%
-+ 0.00%
-+ 0.00%

Medtronic Targets Stroke Prevention Technologies in $380 Million Contego Deal

Benzinga·11/16/2026 17:49:10

Medtronic Plc (NYSE:MDT) on Monday announced its intent to acquire privately held medical device company Contego Medical in a $380 million deal that expands its carotid artery disease and peripheral thrombectomy offerings.

The deal builds on an exclusive U.S. distribution agreement with Contego that Medtronic first announced in January 2025.

Medtronic said the deal fits its strategy of targeted investments that strengthen its core franchises and will broaden patient access to therapies for carotid artery and peripheral vascular disease.

Addressing Stroke Risks in Carotid Artery Disease

Carotid artery disease develops when plaque narrows or blocks the carotid arteries, which serve as the major blood vessels supplying the brain.

When plaque ruptures or embolizes, it causes roughly 20% of all ischemic strokes.

Expanding Vascular and Thrombectomy Technologies

Through the planned acquisition, Medtronic gains Contego’s recently FDA-approved Neuroguard IEP Direct System.

Medtronic called it the first and only transcarotid artery revascularization system combining flow reversal with integrated embolic protection (TCAR-IEP).

In the prospective, multicenter PERFORMANCE III study, patients recorded zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days, according to Medtronic.

Beyond carotid revascularization, the transaction also brings Contego’s Excipio thrombectomy devices into Medtronic’s portfolio.

These devices complement Medtronic’s existing Liberant thrombectomy system in treating peripheral vascular disease.

The deal follows other recent moves. In September, Medtronic announced an approximately $700 million strategic investment in Cornerstone Robotics and agreed to invest up to $80 million in Pi-Cardia.

Medtronic Posts Q1 Beat, 2027 Outlook Raise Validates Growth Inflection

Deal Valuation and Financial Outlook

The deal is valued at $380 million, with potential payments after closing. The company expects to complete the acquisition during the third quarter of its fiscal year.

Medtronic expects the purchase to minimally dilute its adjusted earnings per share in fiscal years 2027 and 2028.

Following that period, the company projects the transaction to turn neutral to accretive.

MDT Price Action: Medtronic shares were up 0.58% at $103.46 at the time of publication Monday, approaching their 52-week high of $106.33, according to Benzinga Pro data.

Photo: Shutterstock